Topics

Eisai and Biogen to Discontinue Phase 3 Clinical Studies of BACE Inhibitor Elenbecestat in Early Alzheimer’s Disease

09:56 EDT 13 Sep 2019 | Speciality Pharma Journal

WOODCLIFF LAKE, N.J., Sept. 13, 2019 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat …

Original Article: Eisai and Biogen to Discontinue Phase 3 Clinical Studies of BACE Inhibitor Elenbecestat in Early Alzheimer’s Disease

NEXT ARTICLE

More From BioPortfolio on "Eisai and Biogen to Discontinue Phase 3 Clinical Studies of BACE Inhibitor Elenbecestat in Early Alzheimer’s Disease"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...